0.325
price up icon2.52%   0.008
pre-market  Pre-market:  .32   -0.005   -1.54%
loading
Bolt Biotherapeutics Inc stock is traded at $0.325, with a volume of 679.31K. It is up +2.52% in the last 24 hours and down -9.97% over the past month. Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
See More
Previous Close:
$0.317
Open:
$0.32
24h Volume:
679.31K
Relative Volume:
2.35
Market Cap:
$12.46M
Revenue:
$7.88M
Net Income/Loss:
$-69.20M
P/E Ratio:
-0.1776
EPS:
-1.83
Net Cash Flow:
$-69.73M
1W Performance:
+2.52%
1M Performance:
-9.97%
6M Performance:
-43.83%
1Y Performance:
-57.52%
1-Day Range:
Value
$0.301
$0.33
1-Week Range:
Value
$0.2895
$0.4624
52-Week Range:
Value
$0.2895
$0.81

Bolt Biotherapeutics Inc Stock (BOLT) Company Profile

Name
Name
Bolt Biotherapeutics Inc
Name
Phone
650-665-9295
Name
Address
900 CHESAPEAKE DRIVE, REDWOOD CITY
Name
Employee
52
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
BOLT's Discussions on Twitter

Compare BOLT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BOLT
Bolt Biotherapeutics Inc
0.325 12.15M 7.88M -69.20M -69.73M -1.83
Biotechnology icon
ONC
Beigene Ltd Adr
238.76 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
434.03 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.2548 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
596.85 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
72.69 5.92B 0 -153.72M -103.81M -2.00

Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-06-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-02-21 Initiated Guggenheim Buy
Mar-02-21 Initiated Morgan Stanley Overweight
Mar-02-21 Initiated SVB Leerink Outperform
Mar-02-21 Initiated Stifel Buy

Bolt Biotherapeutics Inc Stock (BOLT) Latest News

pulisher
May 22, 2025

Lake Street Capital Begins Coverage on Bolt Biotherapeutics (NASDAQ:BOLT) - Defense World

May 22, 2025
pulisher
May 20, 2025

Lake Street Initiates Coverage of Bolt Biotherapeutics (BOLT) with Buy Recommendation - Nasdaq

May 20, 2025
pulisher
May 20, 2025

BOLT: Lake Street Initiates Coverage on Bolt Biotherapeutics wit - GuruFocus

May 20, 2025
pulisher
May 20, 2025

BOLT: Lake Street Initiates Coverage on Bolt Biotherapeutics with Buy Rating | BOLT Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Lake Street Begins Coverage of Bolt Biotherapeutics (BOLT) with Bullish Outlook | BOLT Stock News - GuruFocus

May 20, 2025
pulisher
May 16, 2025

Leerink Partnrs Has Optimistic Outlook of BOLT Q2 Earnings - Defense World

May 16, 2025
pulisher
May 15, 2025

Stifel Nicolaus Lowers Bolt Biotherapeutics (NASDAQ:BOLT) Price Target to $1.00 - Defense World

May 15, 2025
pulisher
May 14, 2025

Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates - MSN

May 14, 2025
pulisher
May 13, 2025

BOLT Stock Target Price Revised to $1 Amid Recent Developments | - GuruFocus

May 13, 2025
pulisher
May 13, 2025

BOLT: Stifel Lowers Price Target on Bolt Biotherapeutics, Mainta - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Bolt Biotherapeutics Reports Q1 2025 Financial Results - TipRanks

May 13, 2025
pulisher
May 12, 2025

BOLT Exceeds Q1 Revenue Expectations with Higher Earnings | BOLT Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot - San Antonio Express-News

May 12, 2025
pulisher
May 12, 2025

Bolt Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025
pulisher
May 12, 2025

Bolt Biotherapeutics Inc (BOLT) Q1 2025 Earnings: EPS of -$0.29 - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times

May 12, 2025
pulisher
May 12, 2025

Bolt Biotherapeutics, Inc. SEC 10-Q Report - TradingView

May 12, 2025
pulisher
May 11, 2025

Bolt Biotherapeutics (BOLT) Expected to Announce Quarterly Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 10, 2025

Biotech Alert: Searches spiking for these stocks today - Yahoo Finance

May 10, 2025
pulisher
May 08, 2025

BOLT: Surge in Interest for Bolt Biotherapeutics Amid Key Develo - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Bolt Biotherapeutics (BOLT) to Host Webcast on Clinical Study an - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Bolt Biotherapeutics (BOLT) to Host Webcast on Clinical Study and Financial Updates | BOLT Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates - The Manila Times

May 08, 2025
pulisher
May 08, 2025

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 ... - Eagle-Tribune

May 08, 2025
pulisher
May 04, 2025

Bolt Biotherapeutics, Inc. (BOLT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates - ACCESS Newswire

May 04, 2025
pulisher
May 01, 2025

Bolt Biotherapeutics amends bylaws, adjusts quorum requirement - Investing.com Australia

May 01, 2025
pulisher
Apr 30, 2025

Innovative Advances in Bolt Biotherapeutics (BOLT) Cancer Therap - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 - The Manila Times

Apr 30, 2025
pulisher
Apr 29, 2025

Bolt Biotherapeutics amends bylaws, adjusts quorum requirement By Investing.com - Investing.com India

Apr 29, 2025
pulisher
Apr 28, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 28, 2025
pulisher
Apr 26, 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - The Manila Times

Apr 26, 2025
pulisher
Apr 25, 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Esca - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Bolt Biotherapeutics reports positive Phase 1 cancer trial results By Investing.com - Investing.com India

Apr 25, 2025
pulisher
Apr 25, 2025

Bolt Biotherapeutics Reports Positive Phase 1 Results for BDC-3042, Demonstrating Safety and Anti-Tumor Activity in Cancer Patients - Nasdaq

Apr 25, 2025
pulisher
Apr 25, 2025

Breakthrough Cancer Drug Achieves 80% Disease Control: Phase 1 Trial Reveals Promising NSCLC Results - Stock Titan

Apr 25, 2025
pulisher
Apr 17, 2025

Bolt Biotherapeutics modifies quorum requirements By Investing.com - Investing.com Canada

Apr 17, 2025
pulisher
Apr 16, 2025

Bolt Biotherapeutics modifies quorum requirements - Investing.com

Apr 16, 2025
pulisher
Apr 12, 2025

BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit - marketscreener.com

Apr 12, 2025
pulisher
Apr 10, 2025

BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 10, 2025
pulisher
Apr 08, 2025

Sept. 3rd Deadline ALERT: Investors Who Lost More Than $100,000 With Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shares Should Contact the Shareholders Foundation - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 08, 2025

BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 07, 2025

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Bolt Biotherapeutics, Inc. (BOLT) - ACCESS Newswire

Apr 07, 2025
pulisher
Apr 04, 2025

Bolt Biotherapeutics stock hits 52-week low at $0.38 By Investing.com - Investing.com UK

Apr 04, 2025
pulisher
Apr 03, 2025

BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 03, 2025
pulisher
Mar 29, 2025

What is HC Wainwright’s Estimate for BOLT Q1 Earnings? - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

What is Leerink Partnrs’ Forecast for BOLT Q1 Earnings? - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

Q3 Earnings Forecast for BOLT Issued By HC Wainwright - Defense World

Mar 28, 2025

Bolt Biotherapeutics Inc Stock (BOLT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$581.44
price down icon 0.60%
$1.39
price up icon 6.92%
$32.50
price down icon 0.28%
$289.00
price down icon 1.22%
$4.2299
price up icon 5.48%
$72.69
price down icon 1.89%
Cap:     |  Volume (24h):